DiaMedica Therapeutics Inc. (DMAC) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 43 days, typically, give or take 19 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 12, 2026after close 43 8-K
Q2 FY2026Mon, Aug 10, 2026after close 41 8-K
Q1 FY2026Wed, May 6, 2026after close 36 8-K
Q4 FY2025Mon, Mar 30, 2026after close 89 8-K
Q3 FY2025Wed, Nov 12, 2025after close 43 8-K
Q2 FY2025Tue, Aug 12, 2025after close 43 8-K
Q1 FY2025Tue, May 13, 2025after close 43 8-K
Q4 FY2024Mon, Mar 17, 2025after close 76 8-K

What they guided beta

Q3 FY2026 "ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial Surpasses 200-Participant Enrollment Threshold; Interim Analysis Expected Q1 2027" exhibit
Q3 FY2026 "We look forward to presenting preliminary results from the first two FGR cohorts at our November 24 key opinion leader (KOL) event and to the ReMEDy2 interim analysis expected in the first quarter of 2027."" exhibit
Q3 FY2026 "The Company expects the interim analysis to be completed in the first quarter of 2027." exhibit
Q3 FY2026 "Based on its current plans, the Company anticipates its current cash, cash equivalents and short-term investments will enable the Company to fund its planned clinical studies and support corporate operations into Q4, 2027." exhibit
Q3 FY2026 "A telephonic replay of the conference call will be available until November 19, 2026, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 7582187#." exhibit
Q2 FY2026 "The Company now has approximately 70 activated sites across the United States, Canada, the United Kingdom, and six European countries added earlier this year, and expects the interim analysis to read out in early 2027." exhibit
Q2 FY2026 "DiaMedica is working with sites in Canada and expects to dose its first patient in the fourth quarter of 2026, and is also preparing to expand the study to the United Kingdom later this year, subject to regulatory authorization and site readiness." exhibit
Q2 FY2026 "Based on its current plans, the Company anticipates its current cash, cash equivalents and short-term investments will enable the Company to fund its planned clinical studies and support corporate operations through 2027." exhibit
Q2 FY2026 "A telephonic replay of the conference call will be available until August 18, 2026, by dialing (880) 770-2030 (US Toll Free) and entering the replay passcode: 2224408#." exhibit
Q2 FY2026 "Part 1a has been completed; the FGR study has initiated enrollment, and its first cohort of 6 participants has been enrolled; and Parts 1b and 2 are expected to initiate in September or October of 2026, as follows:"" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/DMAC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/DMAC

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

DMAC earnings date badge

HTML

<a href="https://veritasdata.dev/company/DMAC/"><img src="https://veritasdata.dev/embed/DMAC.svg" alt="DMAC earnings date" width="240" height="56"></a>

Markdown

[![DMAC earnings date](https://veritasdata.dev/embed/DMAC.svg)](https://veritasdata.dev/company/DMAC/)

Script

<script async src="https://veritasdata.dev/embed/DMAC.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/DMAC"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.